Question 1

What is Global Partners LP stock price today?

Accepted Answer

The current price of Global Partners LP is 48.63 USD — it has increased by 0.85% in the past 24 hours. Watch Global Partners LP stock price performance more closely on the advanced chart.

Question 2

What is Global Partners LP stock ticker?

Accepted Answer

Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange Global Partners LP stocks are traded under the ticker GLP.

Question 3

Is GLP stock price going up?

Accepted Answer

GLP stock has increased by 1.42% in the past week, has increased by 4.58% in the past month, and has decreased by -5.76% in the past year. See more data on GLP chart.

Question 4

What is the analyst recommendation for GLP?

Accepted Answer

As of 28 Jul 2026, out of 1 analyst recommendations, the majority rate GLP as a hold.

Question 5

What is GLP market cap?

Accepted Answer

As of today, GLP has the market capitalization of 1.64B USD. Explore our list of stocks ranked by market cap to compare GLP with other stocks.

Question 6

Does GLP release financial reports?

Accepted Answer

Yes, you can track GLP financials in yearly and quarterly reports on Profit.com.

Question 7

When is GLP next earnings date?

Accepted Answer

GLP is going to release the next earnings report on 07 Aug 2026. Keep track of upcoming events with our Earnings Calendar.

Question 8

What were GLP Earnings for the last quarter?

Accepted Answer

GLP reported earnings of $1.85 per share for the last quarter, higher then the estimate of $0.33 per share, resulting in a 460.61% surprise. The estimated earnings for the next quarter are $1.24 per share. See more details about GLP earnings on Profit.com.

Question 9

What was GLP Revenue for the last quarter?

Accepted Answer

GLP's revenue for the last quarter was 5.32B USD, lower then the estimated 7.46B USD. The estimated revenue for the next quarter is 7.06B USD See more stats in GLP financial reports on Profit.com.

Question 10

What was GLP Net Income for the last quarter?

Accepted Answer

GLP net income for the last quarter is 64.74M USD, while the quarter before that showed 20.13M USD of net income which accounts for 221.70% change. See more stats in GLP financial reports on Profit.com.

Question 11

Does GLP pay dividends?

Accepted Answer

Yes, GLP dividends are paid quarterly. The last dividend per share was 3.03. As of today, Dividend Yield (TTM)% is 6.27%.

Question 12

How many employees does GLP have?

Accepted Answer

As of 28 Jul 2026, GLP employs approximately 3265 employees. Check out if GLP is on our list of largest employers.

Question 13

What is GLP EBITDA?

Accepted Answer

EBITDA, which measures a company's operating performance, reflects its efficiency improvements. GLP EBITDA is 422.75M USD, with a current EBITDA margin of 0.67%. See more stats in GLP financial reports on Profit.com.

Question 14

How to buy GLP stocks?

Accepted Answer

Like other stocks, GLP shares are traded on stock exchanges such as NYSE. The easiest way to buy them is through an online stock broker. Simply open an account, follow the broker's procedures, and start trading. Alternatively, you can practice trading Tesla stock on Profit.com in Playtrade Tournaments or choose a recommended broker to trade directly.

Question 15

Should I invest in GLP stock?

Accepted Answer

Investing in stocks requires thorough research, including analyzing the company’s financials, related news, and technical analysis. Currently, Tesla's technical analyst recommendations show a hold rating.

Before investing in GLP, consider subscribing to Profit PRO where can practice trading in Playtrade Tournaments, access AI-powered daily market insights, copy expertly handpicked Watchlists, and follow Billionaire Portfolios.

Global Partners LP

Logistics giants are racing to keep up with healthcare boom as GLP-1s highlight need for cold storage

Jim Cramer says he's standing by Eli Lilly after rival's GLP-1 lawsuit. Here's why

Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising - CNBC

A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss - CNBC

Why breakthrough GLP-1 weight loss pills may be a bad thing for employer insurance coverage

As the GLP-1 race heats up, how can investors position themselves for the next wave of innovation? (LLY:NYSE) - Seeking Alpha

Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage - CNBC

Amazon launches GLP-1 weight loss program, promising'fast, convenient' access

Eli Lilly taps into its GLP-1 windfall, while Honeywell sheds a lower-margin unit

RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves - CNBC

As millions lose weight on GLP-1s, they're starting to turn to retailers to refresh their wardrobes

Novo Nordisk's explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment

GLP-1 drugs are changing how Americans eat. Food companies are racing to catch up

Healthy Returns: Stopping GLP-1s raises risk of heart attack, stroke and death, study says - CNBC

Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients

Fancy clothes, mealtime alarms and Disney princess gigs: How GLP-1s are changing people's lives in unexpected ways

Healthy Returns: FDA chief Marty Makary on compounded GLP-1s, vaccines and China

What the initial frenzy over GLP-1 drugs can teach us about the current market

What signal Lilly sends by stockpiling its GLP-1 weight loss pills ahead of FDA approval

Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026

This top stock-picker spotted Nvidia and GLP-1s early — and made over 200%. Here’s what he’s buying now.

Half of GLP-1 users ditch their injections — and some are turning to other weight-loss methods instead

Novo Nordisk CEO explains why new GLP-1 pill expands access to the weight loss drugs

Novo Nordisk Launches $149 Wegovy Pill, Expanding Access to GLP-1 Weight-Loss Drugs

FDA approves first GLP-1 pill for weight loss - Axios

FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk - CNBC

GRVT GLP Strategy Reopened, Funding Cap Raised to $7.5M on Grvt’s Decentralized Perpetual Platform

There’s still hope GLP-1 drugs could slow the second-biggest type of dementia

Novo Nordisk’s oral GLP-1 drug didn’t work on Alzheimer’s as hoped, and the stock tumbles

Is GLP-1 the new AI? Drugmaker Eli Lilly briefly joined the $1 trillion market cap club.

Eli Lilly and Novo Nordisk stocks fall as Trump says he wants $150 price for GLP-1s

Tariffs and GLP-1s are keeping people from dining out. An analyst tries to find the positives.

GLP-1 drugs could save millions of lives — and spark a pension crisis

Hacked Perp DEX GMX to Repay $44M to Arbitrum GLP Holders After Exploit

Why GLP-1s could become the "everything drug" - Axios

GMX Recovers $42 Million GLP Funds on Arbitrum After V1 Vulnerability Attack

GMX Hack Exploits GLP Token Vulnerability, Potential Partial Recovery of Stolen Ethereum

GMX Faces $40 Million V1 GLP Pool Exploit, Raising Questions on DeFi Leverage Security

GMX V1 Faces Possible Exploit Impacting GLP Pool Amid Ongoing Crypto Security Concerns in 2025

GMX V1 GLP Pool on Arbitrum Hit by $40M Attack; Trading Suspended to Protect Users

Market Voices: July Fed rate cut eyed, GLP-1s, Darden, Aflac, JPMorgan

Just how many Americans are taking GLP-1s now - Axios

Hims & Hers shares tumble 18% as margin miss adds to concerns about GLP-1 business

Largest-ever Ozempic and GLP-1 drug study finds they lower risk of 42 health conditions, including heart attacks and Alzheimer’s disease - Fortune

What's next for GLP-1 weight-loss drugs in 2025? https://t.co/LPstciGZ32 https://t.co/mVitY14CTY

Hims & Hers shares rally on results, but execs say GLP-1 drug shortage ‘is not abating’

WeightWatchers’ stock soars after adding compounded GLP-1 treatment to its offering

Obesity drugs in kindergarten? Novo Nordisk GLP-1 drug works for kids as young as 6, study finds.

Obesity drugs’ next wave: These companies could snag 20% of GLP-1 market, analysts say

For Alzheimer’s patients, this Novo Nordisk GLP-1 drug slows cognitive decline, study finds

FAQs